Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease

BACKGROUND: Cardiovascular and renal benefits of sodium glucose co-transporter 2 inhibitors (SGLT2i) have been clearly demonstrated. However, studies comparing the effects of dapagliflozin and empagliflozin are scarce. In addition, relatively few studies have analyzed the effects of SGLT2i in diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jayoung, Hwang, In-Chang, Choi, Hong-Mi, Yoon, Yeonyee E., Cho, Goo-Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576049/
https://www.ncbi.nlm.nih.gov/pubmed/36251654
http://dx.doi.org/10.1371/journal.pone.0269414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576049/
https://www.ncbi.nlm.nih.gov/pubmed/36251654
http://dx.doi.org/10.1371/journal.pone.0269414

Ejemplares similares